These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27843206)

  • 1. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.
    Shenoy N; Kohli M
    Indian J Urol; 2016; 32(4):257-261. PubMed ID: 27843206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
    Vale CL; Fisher DJ; Godolphin PJ; Rydzewska LH; Boher JM; Burdett S; Chen YH; Clarke NW; Fizazi K; Gravis G; James ND; Liu G; Matheson D; Murphy L; Oldroyd RE; Parmar MKB; Rogozinska E; Sfumato P; Sweeney CJ; Sydes MR; Tombal B; White IR; Tierney JF;
    Lancet Oncol; 2023 Jul; 24(7):783-797. PubMed ID: 37414011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
    Fizazi K; Jenkins C; Tannock IF
    Ann Oncol; 2015 Aug; 26(8):1660-7. PubMed ID: 26002607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone naïve metastatic prostate cancer: How to treat it?
    Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
    Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront Chemotherapy for Metastatic Prostate Cancer.
    Lam ET; Flaig TW
    Oncology (Williston Park); 2015 Dec; 29(12):956-62. PubMed ID: 26676900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
    van Soest RJ; de Wit R
    BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
    Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
    Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Morris MJ; Rumble RB; Basch E; Hotte SJ; Loblaw A; Rathkopf D; Celano P; Bangs R; Milowsky MI
    J Clin Oncol; 2018 May; 36(15):1521-1539. PubMed ID: 29608397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
    Xu L; Pachynski RK
    Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
    Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
    Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Mutlu H; Bozcuk H
    J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.